Extracranial oligometastases: A subset of metastases curable with stereotactic radiotherapy

Journal of Clinical Oncology

Volumn 31, Issue 11, 2013, Pages 1384-1390

  Corbin, Kimberly S ^a   Hellman, Samuel ^a   Weichselbaum, Ralph R ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; INTERLEUKIN 2; IPILIMUMAB;

ADRENAL METASTASIS; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CLEAR CELL CARCINOMA; COLORECTAL CANCER; DISEASE SPECIFIC SURVIVAL; DRUG MEGADOSE; HUMAN; LIVER METASTASIS; LONG TERM SURVIVAL; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; MELANOMA; METASTASIS; METASTASIS RESECTION; NEPHRECTOMY; NOTE; OLIGOMETASTASIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT MONITORING; PHENOTYPE; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; STEREOTACTIC BODY RADIATION THERAPY; TUMOR MICROENVIRONMENT;

CLINICAL TRIALS AS TOPIC; HUMANS; LUNG NEOPLASMS; MELANOMA; NEOPLASM METASTASIS; RADIOSURGERY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84876094979     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.45.9651     Document Type: Note

References (105)

1. Hellman S, Weichselbaum RR: Oligometastases. J Clin Oncol 13:8-10, 1995
2. Weichselbaum RR, Hellman S: Oligometastases revisited. Nat Rev Clin Oncol 8:378-382, 2011
3. Saxman SB, Finch D, Gonin R, et al: Long-term follow-up of a phase III study of three versus four cycles of bleomycin, etoposide, and cisplatin in favorable-prognosis germ-cell tumors: The Indian University experience. J Clin Oncol 16:702-706, 1998 (Pubitemid 28135618)
4. Culine S, Kerbrat P, Kramar A, et al: Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: A randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP). Ann Oncol 18:917-924, 2007 (Pubitemid 47054091)
5. Niibe Y, Hayakawa K: Oligometastases and oligo-recurrence: The new era of cancer therapy. Jpn J Clin Oncol 40:107-111, 2010
6. Nibbe YNT, Inoue T, Karasawa K, et al: Oligometastases of brain only in patients with non-small cell lung cancer (NSCLC) treated with stereotactic irradiation (STI): A multi-institutional study. Int J Radiat Oncol Biol Phys 78:S497, 2010 (abstr 2656)
7. Norton L, Simon R: The Norton-Simon hypothesis revisited. Cancer Treat Rep 70:163-169, 1986 (Pubitemid 16140378)
8. Andrews DW, Scott CB, Sperduto PW, et al: Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: Phase III results of the RTOG 9508 randomised trial. Lancet 363:1665-1672, 2004 (Pubitemid 38670323)
9. Sperduto PW, Kased N, Roberge D, et al: Summary report on the graded prognostic assessment: An accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol 30:419-425, 2012
10. Patchell RA, Tibbs PA, Walsh JW, et al: A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 322:494-500, 1990 (Pubitemid 20067825)
11. Barney JD, Churchill EJ: Adenocarcinoma of the kidney with metastasis to the lung cured by nephrectomy and lobectomy. J Urol 42:269-276, 1939
12. Rees M, Tekkis PP, Welsh FK, et al: Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: A multifactorial model of 929 patients. Ann Surg 247:125-135, 2008
13. Fong Y, Fortner J, Sun RL, et al: Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: Analysis of 1001 consecutive cases. Ann Surg 230:309-318, 1999; discussion 318-321
14. Pawlik TM, Scoggins CR, Zorzi D, et al: Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg 241:715-722, 2005; discussion 722-724
15. Carpizo DR, D'Angelica M: Liver resection for metastatic colorectal cancer in the presence of extrahepatic disease. Ann Surg Oncol 16:2411-2421, 2009
16. de Haas RJ, Wicherts DA, Flores E, et al: R1 resection by necessity for colorectal liver metastases: Is it still a contraindication to surgery? Ann Surg 248:626-637, 2008
17. Elias D, Cavalcanti A, Sabourin JC, et al: Resection of liver metastases from colorectal cancer: The real impact of the surgical margin. Eur J Surg Oncol 24:174-179, 1998 (Pubitemid 28260607)
18. Elias D, Cavalcanti de Albuquerque A, Eggenspieler P, et al: Resection of liver metastases from a noncolorectal primary: Indications and results based on 147 monocentric patients. J Am Coll Surg 187:487-493, 1998
19. de Jong MC, Pulitano C, Ribero D, et al: Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: An international multi-institutional analysis of 1669 patients. Ann Surg 250:440-448, 2009
20. Choong PF, Pritchard DJ, Rock MG, et al: Survival after pulmonary metastasectomy in soft tissue sarcoma: Prognostic factors in 214 patients. Acta Orthop Scand 66:561-568, 1995 (Pubitemid 26015389)
21. Casiraghi M, De Pas T, Maisonneuve P, et al: A 10-year single-center experience on 708 lung metastasectomies: The evidence of the "international registry of lung metastases." J Thorac Oncol 6:1373-1378, 2011
22. Pfannschmidt J, Muley T, Hoffmann H, et al: Prognostic factors and survival after complete resection of pulmonary metastases from colorectal carcinoma: Experiences in 167 patients. J Thorac Cardiovasc Surg 126:732-739, 2003 (Pubitemid 37151956)
23. Pfannschmidt J, Hoffmann H, Muley T, et al: Prognostic factors for survival after pulmonary resection of metastatic renal cell carcinoma. Ann Thorac Surg 74:1653-1657, 2002 (Pubitemid 35222660)
24. Kanemitsu Y, Kato T, Hirai T, et al: Preoperative probability model for predicting overall survival after resection of pulmonary metastases from colorectal cancer. Br J Surg 91:112-120, 2004 (Pubitemid 38122060)
25. Petersen RP, Hanish SI, Haney JC, et al: Improved survival with pulmonary metastasectomy: An analysis of 1720 patients with pulmonary metastatic melanoma. J Thorac Cardiovasc Surg 133:104-110, 2007
26. Saito Y, Omiya H, Kohno K, et al: Pulmonary metastasectomy for 165 patients with colorectal carcinoma: A prognostic assessment. J Thorac Cardiovasc Surg 124:1007-1013, 2002 (Pubitemid 35253251)
27. Scheele J, Stang R, Altendorf-Hofmann A, et al: Resection of colorectal liver metastases. World J Surg 19:59-71, 1995
28. Long-term results of lung metastasectomy: Prognostic analyses based on 5206 cases - The International Registry of Lung Metastases. J Thorac Cardiovasc Surg 113:37-49, 1997
29. Kim SH, Brennan MF, Russo P, et al: The role of surgery in the treatment of clinically isolated adrenal metastasis. Cancer 82:389-394, 1998
30. Porte H, Siat J, Guibert B, et al: Resection of adrenal metastases from non-small cell lung cancer: A multicenter study. Ann Thorac Surg 71:981-985, 2001 (Pubitemid 32210414)
31. Mercier O, Fadel E, de Perrot M, et al: Surgical treatment of solitary adrenal metastasis from non-small cell lung cancer. J Thorac Cardiovasc Surg 130:136-140, 2005 (Pubitemid 40941681)
32. Burt M, Wronski M, Arbit E, et al: Resection of brain metastases from non-small-cell lung carcinoma: Results of therapy-Memorial Sloan-Kettering Cancer Center Thoracic Surgical Staff. J Thorac Cardiovasc Surg 103:399-410, 1992; discussion 410-411
33. Bonnette P, Puyo P, Gabriel C, et al: Surgical management of non-small cell lung cancer with synchronous brain metastases. Chest 119:1469-1475, 2001 (Pubitemid 32686031)
34. Nordlinger B, Guiguet M, Vaillant JC, et al: Surgical resection of colorectal carcinoma metastases to the liver: A prognostic scoring system to improve case selection, based on 1568 patients - Association Française de Chirurgie. Cancer 77:1254-1262, 1996
35. Tomlinson JS, Jarnagin WR, DeMatteo RP, et al: Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol 25:4575-4580, 2007 (Pubitemid 350035315)
36. Wagner JS, Adson MA, Van Heerden JA, et al: The natural history of hepatic metastases from colorectal cancer: A comparison with resective treatment. Ann Surg 199:502-508, 1984 (Pubitemid 14105105)
37. Mountain CF, McMurtrey MJ, Hermes KE: Surgery for pulmonary metastasis: A 20-year experience. Ann Thorac Surg 38:323-330, 1984 (Pubitemid 14012544)
38. Rudra S: Patterns of failure in esophageal cancer: What is the likelihood of limited metastatic failure. Int J Radiat Oncol Biol Phys 84:S628, 2012 (abstr 3091)
39. Mehta N, Mauer AM, Hellman S, et al: Analysis of further disease progression in metastatic non-small cell lung cancer: Implications for locoregional treatment. Int J Oncol 25:1677-1683, 2004
40. Gomez DR, Niibe Y, Chang JY: Oligometastatic disease at presentation or recurrence for nonsmall cell lung cancer. Pulm Med [epub ahead of print on July 30, 2012]
41. Tait CR, Waterworth A, Loncaster J, et al: The oligometastatic state in breast cancer: Hypothesis or reality. Breast 14:87-93, 2005 (Pubitemid 40353035)
42. Kao J, Packer S, Vu HL, et al: Phase 1 study of concurrent sunitinib and image-guided radiotherapy followed by maintenance sunitinib for patients with oligometastases: Acute toxicity and preliminary response. Cancer 115:3571-3580, 2009
43. Singh D, Yi WS, Brasacchio RA, et al: Is there a favorable subset of patients with prostate cancer who develop oligometastases? Int J Radiat Oncol Biol Phys 58:3-10, 2004 (Pubitemid 38010330)
44. Paget S: The distribution of secondary growths in cancer of the breast. Lancet 1:571-573, 1889
45. Axelson H, Fredlund E, Ovenberger M, et al: Hypoxia-induced dedifferentiation of tumor cells: A mechanism behind heterogeneity and aggressiveness of solid tumors. Semin Cell Dev Biol 16:554-563, 2005 (Pubitemid 41247879)
46. Fidler IJ: The organ microenvironment and cancer metastasis. Differentiation 70:498-505, 2002
47. Bristow RG, Hill RP: Hypoxia and metabolism: Hypoxia, DNA repair and genetic instability. Nat Rev Cancer 8:180-192, 2008 (Pubitemid 351301853)
48. Khong HT, Restifo NP: Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol 3:999-1005, 2002 (Pubitemid 35363649)
49. Chiang AC, Massagué J: Molecular basis of metastasis. N Engl J Med 359:2814-2823, 2008
50. Gupta GP, Massagué J: Cancer metastasis: Building a framework. Cell 127:679-695, 2006 (Pubitemid 44781029)
51. Nguyen DX, Massagué J: Genetic determinants of cancer metastasis. Nat Rev Genet 8:341-352, 2007 (Pubitemid 46625811)
52. Fidler IJ: Metastasis: Quantitative analysis of distribution and fate of tumor embolilabeled with 125 I-5-iodo-2′-deoxyuridine. J Natl Cancer Inst 45:773-782, 1970
53. Brown PO, Palmer C: The preclinical natural history of serous ovarian cancer: Defining the target for early detection. PLoS Med 6:e1000114, 2009
54. Yachida S, Jones S, Bozic I, et al: Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467:1114-1117, 2010
55. Fidler IJ, Kripke ML: Metastasis results from preexisting variant cells within a malignant tumor. Science 197:893-895, 1977 (Pubitemid 8168759)
56. Li Y, Tang ZY, Ye SL, et al: Establishment of cell clones with different metastatic potential from the metastatic hepatocellular carcinoma cell line MHCC97. World J Gastroenterol 7:630-636, 2001 (Pubitemid 32994410)
57. Shindo-Okada N, Takeuchi K, Nagamachi Y: Establishment of cell lines with high- and low-metastatic potential from PC-14 human lung adenocarcinoma. Jpn J Cancer Res 92:174-183, 2001 (Pubitemid 32241775)
58. Lussier YA, Xing HR, Salama JK, et al: MicroRNA expression characterizes oligometastasis(es). PLoS One 6:e28650, 2011
59. Lussier YA, Khodarev NN, Regan K, et al: Oligo- and polymetastatic progression in lung metastasis(es) patients is associated with specific microRNAs. PLoS One 7:e50141, 2012
60. Wuttig D, Baier B, Fuessel S, et al: Gene signatures of pulmonary metastases of renal cell carcinoma reflect the disease-free interval and the number of metastases per patient. Int J Cancer 125:474-482, 2009
61. Gadd MA, Casper ES, Woodruff JM, et al: Development and treatment of pulmonary metastases in adult patients with extremity soft tissue sarcoma. Ann Surg 218:705-712, 1993 (Pubitemid 24005813)
62. Ksienski D, Woods R, Speers C, et al: Patterns of referral and resection among patients with liver-only metastatic colorectal cancer (MCRC). Ann Surg Oncol 17:3085-3093, 2010
63. Dorn P, Meriwether A, LeMieux M, et al: Patterns of distant failure and progression in breast cancer: Implications for the treatment of oligometastatic disease. Int J Radiat Oncol 81:S643, 2011 (abstr 2903)
64. MacManus MP, Hicks RJ, Matthews JP, et al: High rate of detection of unsuspected distant metastases by PET in apparent stage III non-small-cell lung cancer: Implications for radical radiation therapy. Int J Radiat Oncol Biol Phys 50:287-293, 2001 (Pubitemid 32472257)
65. Tanvetyanon T, Robinson LA, Schell MJ, et al: Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small-cell lung cancer: A systematic review and pooled analysis. J Clin Oncol 26:1142-1147, 2008
66. Blomgren H, Lax I, Näslund I, et al: Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator: Clinical experience of the first thirty-one patients. Acta Oncol 34:861-870, 1995
67. Wulf J, Haedinger U, Oppitz U, et al: Stereotactic radiotherapy for primary lung cancer and pulmonary metastases: A noninvasive treatment approach in medically inoperable patients. Int J Radiat Oncol Biol Phys 60:186-196, 2004 (Pubitemid 39165484)
68. Hoyer M, Roed H, Traberg Hansen A, et al: Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol 45:823-830, 2006 (Pubitemid 44423128)
69. Hof H, Hoess A, Oetzel D, et al: Stereotactic single-dose radiotherapy of lung metastases. Strahlenther Onkol 183:673-678, 2007 (Pubitemid 350175409)
70. Katz AW, Carey-Sampson M, Muhs AG, et al: Hypofractionated stereotactic body radiation therapy (SBRT) for limited hepatic metastases. Int J Radiat Oncol Biol Phys 67:793-798, 2007 (Pubitemid 46215888)
71. Rusthoven KE, Kavanagh BD, Burri SH, et al: Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. J Clin Oncol 27:1579-1584, 2009
72. Rusthoven KE, Kavanagh BD, Cardenes H, et al: Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol 27:1572-1578, 2009
73. Kang JK, Kim MS, Kim JH, et al: Oligometastases confined one organ from colorectal cancer treated by SBRT. Clin Exp Metastasis 27:273-278, 2010
74. Okunieff P, Petersen AL, Philip A, et al: Stereotactic body radiation therapy (SBRT) for lung metastases. Acta Oncol 45:808-817, 2006 (Pubitemid 44423126)
75. Lee MT, Kim JJ, Dinniwell R, et al: Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol 27:1585-1591, 2009
76. Milano MT, Katz AW, Zhang H, et al: Oligometastases treated with stereotactic body radiotherapy: Long-term follow-up of prospective study. Int J Radiat Oncol Biol Phys 83:878-886, 2011
77. Salama JK, Hasselle MD, Chmura SJ, et al: Stereotactic body radiotherapy for multisite extracranial oligometastases: Final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. Cancer 118:2962-2970, 2012
78. Bae SH, Kim MS, Cho CK, et al: High dose stereotactic body radiotherapy using three fractions for colorectal oligometastases. J Surg Oncol 106:138-143, 2012
79. Norihisa Y, Nagata Y, Takayama K, et al: Stereotactic body radiotherapy for oligometastatic lung tumors. Int J Radiat Oncol Biol Phys 72:398-403, 2008
80. Lo SS, Sahgal A, Wang JZ, et al: Stereotactic body radiation therapy for spinal metastases. Discov Med 9:289-296, 2010
81. Chawla S, Chen Y, Katz AW, et al: Stereotactic body radiotherapy for treatment of adrenal metastases. Int J Radiat Oncol Biol Phys 75:71-75, 2009
82. Timmerman RD, Kavanagh BD, Cho LC, et al: Stereotactic body radiation therapy in multiple organ sites. J Clin Oncol 25:947-952, 2007 (Pubitemid 350002860)
83. Lo SS, Clarke JW, Grecula JC, et al: Stereotactic radiosurgery alone for patients with 1-4 radioresistant brain metastases. Med Oncol 28:S439-S444, 2011 (suppl 1)
84. Milano MT, Katz AW, Muhs AG, et al: A prospective pilot study of curative-intent stereotactic body radiation therapy in patients with 5 or fewer oligometastatic lesions. Cancer 112:650-658, 2008 (Pubitemid 351186206)
85. Milano MT, Zhang H, Metcalfe SK, et al: Oligometastatic breast cancer treated with curative-intent stereotactic body radiation therapy. Breast Cancer Res Treat 115:601-608, 2009
86. Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic Tumors (SABR-COMET). http://clinicaltrials.gov/ct2/show/ NCT01446744
87. Radiosurgery for Patients Recurrent Oligometastatic Disease. http://clinicaltrials.gov/ct2/show/NCT01345552
88. Radiosurgery for Patients With Oligometastatic Disease at Initial Presentation. http://www.clinicaltrials.gov/ct2/show/NCT01345539
89. Concurrent Ipilimumab and Stereotactic Ablative Radiation Therapy (SART) for Oligometastatic But Unresectable Melanoma. http://clinicaltrials.gov/ct2/ show/NCT01565837
90. Stereotactic Body Radiation Therapy (SBRT) in Metastatic Non-Small Cell Lung Cancer: http://clinicaltrials.gov/ct2/show/NCT01185639
91. PulMiCC. http://www.rbht.nhs.uk/PulMiCC/
92. Downey RJ, Ng KK, Kris MG, et al: A phase II trial of chemotherapy and surgery for non-small cell lung cancer patients with a synchronous solitary metastasis. Lung Cancer 38:193-197, 2002 (Pubitemid 35154384)
93. De Ruysscher D, Wanders R, van Baardwijk A, et al: Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases: Longterm results of a prospective phase II trial (Nct01282450). J Thorac Oncol 7:1547-1555, 2012
94. Kirkpatrick JP, Meyer JJ, Marks LB: The linear-quadratic model is inappropriate to model high dose per fraction effects in radiosurgery. Semin Radiat Oncol 18:240-243, 2008
95. Garcia-Barros M, Paris F, Cordon-Cardo C, et al: Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 300:1155-1159, 2003 (Pubitemid 36583102)
96. García-Barros M, Thin TH, Maj J, et al: Impact of stromal sensitivity on radiation response of tumors implanted in SCID hosts revisited. Cancer Res 70:8179-8186, 2010
97. Lugade AA, Moran JP, Gerber SA, et al: Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol 174:7516-7523, 2005 (Pubitemid 40806254)
98. Apetoh L, Ghiringhelli F, Tesniere A, et al: Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 13:1050-1059, 2007 (Pubitemid 47517504)
99. Lee Y, Auh SL, Wang Y, et al: Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: Changing strategies for cancer treatment. Blood 114:589-595, 2009
100. Demaria S, Ng B, Devitt ML, et al: Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys 58:862-870, 2004 (Pubitemid 38221143)
101. Dewan MZ, Galloway AE, Kawashima N, et al: Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res 15:5379-5388, 2009
102. Takaya M, Niibe Y, Tsunoda S, et al: Abscopal effect of radiation on toruliform para-aortic lymph node metastases of advanced uterine cervical carcinoma: A case report. Anticancer Res 27:499-503, 2007 (Pubitemid 46374969)
103. Okuma K, Yamashita H, Niibe Y, et al: Abscopal effect of radiation on lung metastases of hepatocellular carcinoma: A case report. J Med Case Rep 5:111, 2011
104. Postow MA, Callahan MK, Barker CA, et al: Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 366:925-931, 2012
105. Seung SK, Curti BD, Crittenden M, et al: Phase 1 study of stereotactic body radiotherapy and interleukin-2: Tumor and immunological responses. Sci Transl Med 4:137ra74, 2012